🔴 Taysha Gene Therapies is trading 8.25% down in pre-market with no clear catalyst identified

Taysha Gene Therapies is trading at $4.00, down 8.25% in pre-market, with the reason for the decline unclear.

• No clear new company-specific announcement explaining the November 5 pre-market decline surfaced; the company’s press-release page listed an October 2 release as its latest announcement.
• XBI was nearly flat in pre-market despite its prior-session gain, so biotech-sector strength does not explain the opposite-direction move.
• Available sources do not establish a specific catalyst or pre-market trading volume.